Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 Adjuvant Therapy in Non-Muscle-Invasive Bladder Cancer
NCT05232136Phase 2Recruiting
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of OH2 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Jul 2022; status: recruiting.
02
Drugs
OH2
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT05232136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05232136.